Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Am J Obstet Gynecol. 2019 Nov 6;222(5):478.e1–478.e17. doi: 10.1016/j.ajog.2019.10.103

Figure 2.

Figure 2

Adjusted prospective association between body mass index at baseline and the risk of vasomotor symptoms at three-year follow-up, stratified by menopausal status at three-year follow-up (data from ALSWH, NSHD, SWAN and WHITEHALL; pre- or perimenopause: n=3,554; postmenopause: n=3,966). Relative risk ratio (RRR) and their 95% confidence intervals (95% CI) were adjusted for use of menopausal hormone therapy at three-year follow-up, race/ethnicity/region, education, smoking status, and vasomotor symptoms at baseline.